Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.71 |
| ▸ | CA1 | P00915 | 1/20 | 0.71 |
| ▸ | CA2 | P00918 | 1/20 | 0.71 |
| ▸ | CA7 | P43166 | 1/20 | 0.71 |
| ▸ | CA9 | Q16790 | 1/20 | 0.71 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.71 |
| ▸ | CYP1A1 | P04798 | 7/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1963842 | 0.91 | CA12 (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL23115 | 0.84 | CA2 (0.67) | CA12CA1CA2CA7CA9 | |
| 1,2,4-Trimethoxybenzene SCHEMBL27777905 | 0.84 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| 1,2,4-Trimethoxybenzene SCHEMBL29350371 | 0.84 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| 1,2,4-Trimethoxybenzene SCHEMBL481491 | 0.84 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8402696 | 0.83 | CA12 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7802157 | 0.81 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5748457 | 0.81 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL958654 | 0.81 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2002833 | 0.81 | CA12 (0.50) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118302417-A | NLRP3 inhibitors | PTC医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-113122269-B | Ultraviolet light absorber | 光学转变公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-112638380-B | Cerebellar protein (CRBN) ligands | 达纳-法伯癌症研究所有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-117285524-A | Substituted 4-amino isoindoline compounds, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2023-12-26 | — | — | CN | disclosed |
| CN-115594642-A | Az Ji Ruige triazole derivative and application thereof in resisting breast cancer | 广西医科大学（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-113122269-A | Ultraviolet light absorber | 光学转变公司 | 2021-07-16 | — | — | CN | disclosed |
| CN-112888693-A | Polycyclic compound and organic electroluminescent device comprising same | 出光兴产株式会社 | 2021-06-01 | — | — | CN | disclosed |
| CN-107109227-B | Ultraviolet light absorber | 光学转变公司 | 2021-05-04 | — | — | CN | disclosed |
| CN-112638380-A | Cereblon (CRBN) ligands | 达纳-法伯癌症研究所有限公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-112334466-A | Compound (I) | CTXT私人有限公司 | 2021-02-05 | — | — | CN | disclosed |
| US-20030208067-A1 | Inhibitors of protein kinase for the treatment of disease | LG BIOMEDICAL INSTITUTE | 2003-11-06 | — | — | US | disclosed |
| US-20030187007-A1 | Inhibitors of protein kinase for the treatment of disease | LG BIOMEDICAL INSTITUTE | 2003-10-02 | — | — | US | disclosed |
| WO-2002096867-A2 | INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE | LG BIOMEDICAL INSTITUTE (US) | 2002-12-05 | — | — | WO | disclosed |
| EP-1216235-A1 | QUINAZOLINONES | MERCK PATENT GmbH (DE) | 2002-06-26 | — | — | EP | disclosed |
| EP-1216233-A1 | QUINAZOLINONES | MERCK PATENT GmbH (DE) | 2002-06-26 | — | — | EP | disclosed |
| EP-1196640-A2 | ELECTRON-DEFICIENT NITROGEN HETEROCYCLE-SUBSTITUTED FLUORESCEIN DYES | Applera Corporation (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001057264-A2 | ELECTRON-DEFICIENT NITROGEN HETEROCYCLE-SUBSTITUTED FLUORESCEIN DYES | APPLERA CORPORATION (US) | 2001-08-09 | — | — | WO | disclosed |
| US-6221604-B1 | CONJUGATED TO SUBSTRATES SUCH AS NUCLEOSIDES OR NUCLEOTIDES AND USED AS DETECTION LABELS IN MOLECULAR BIOLOGY EXPERIMENTS; ENERGY TRANSFER DYE | PE CORPORATION | 2001-04-24 | — | — | US | disclosed |
| WO-2001023365-A1 | QUINAZOLINONES | MERCK PATENT GMBH (DE) | 2001-04-05 | — | — | WO | disclosed |
| WO-2001023364-A1 | QUINAZOLINONES | MERCK PATENT GMBH (DE) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030208067-A1 | Inhibitors of protein kinase for the treatment of disease | MAP3K20, MAP3K1, MAP3K2 | CA12 4661/4885CA1 4632/4885CA2 2156/4885 |
| US-20030187007-A1 | Inhibitors of protein kinase for the treatment of disease | MAP3K20, MAP3K1, MAP3K2 | CA12 4661/4885CA1 4632/4885CA2 2156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.